On Monday 2 December, the European Commission’s Health Emergency Preparedness and Response Authority (HERA) signed a joint framework contract with the pharmaceutical company Gilead, on behalf of 13 countries, for the supply of 2,250,000 vials of Veklury (Remdésivir).
This antiviral treatment can be used to treat Covid-19 in hospitalised adults and adolescents with pneumonia requiring supplemental oxygen, or to treat adults at increased risk of progression to severe cases of Covid-19.